Literature DB >> 10847440

Enhancement of poly-adenosine diphosphate-ribosylation in human hepatocellular carcinoma.

F Nomura1, M Yaguchi, A Togawa, M Miyazaki, K Isobe, M Miyake, M Noda, T Nakai.   

Abstract

BACKGROUND: Poly-adenosine diphosphate (ADP)-ribosylation, catalysed by poly(ADP-ribose) polymerase (PARP), is a post-translational modification of nuclear proteins and is involved in a wide range of biological processes including DNA repair, cell proliferation and malignant transformation. Alteration of this reaction in human hepatocellular carcinoma (HCC) is of interest, but has not yet been explored. The aim of this study was to evaluate poly-ADP-ribosylation and to compare the expression of PARP in HCC and adjacent non-tumour tissues.
METHODS: Tumorous and adjacent non-tumorous tissues were obtained from five consecutive patients with HCC during surgery for tumour resection. Tissue homogenates were subjected to ADP-ribosylation with [32P]-nicotinamide adenine dinucleotide. The ADP-ribosylated proteins were separated by sodium dodecylsulfate-polyacrylamide gel electrophoresis, followed by autoradiography. Expression of PARP was also evaluated by western blotting.
RESULTS: Several proteins were ADP-ribosylated in human HCC tissues. Notably, the radiolabelling of a 116-kDa protein was remarkably greater than that in adjacent non-tumorous tissues (86.5 +/- 35.2 arbitrary units by densitometry vs 12.2 +/- 9.9, mean +/- SD, n = 5, P < 0.02). The radiolabelling of the 116-kDa protein was decreased in the presence of PARP inhibitors in a concentration-dependent manner. Immunoblot analyses revealed that the radiolabelled protein was PARP and that its expression was significantly greater in HCC than in adjacent non-tumorous tissues (333 +/- 204% of non-tumorous tissue, P < 0.05).
CONCLUSIONS: We found that poly-ADP-ribosylation and PARP expression were significantly increased in human HCC compared with those in adjacent non-tumorous tissues in surgically obtained specimens.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10847440     DOI: 10.1046/j.1440-1746.2000.02193.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  22 in total

1.  Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.

Authors:  Thomas O'Brien; Jason Oeh; Yang Xiao; Xiaorong Liang; Alexander Vanderbilt; Ann Qin; Lulu Yang; Leslie B Lee; Justin Ly; Ely Cosino; Jennifer A LaCap; Annie Ogasawara; Simon Williams; Michelle Nannini; Bianca M Liederer; Peter Jackson; Peter S Dragovich; Deepak Sampath
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

2.  O Labeling for a Quantitative Proteomic Analysis of Glycoproteins in Hepatocellular Carcinoma.

Authors:  Raghothama Chaerkady; Paul J Thuluvath; Min-Sik Kim; Anuradha Nalli; Perumal Vivekanandan; Jessica Simmers; Michael Torbenson; Akhilesh Pandey
Journal:  Clin Proteomics       Date:  2008-07-18       Impact factor: 3.988

3.  PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First In-Human Studies.

Authors:  Loren S Michel; Samantha Dyroff; Frank J Brooks; Katherine J Spayd; Sora Lim; Jacquelyn T Engle; Sharon Phillips; Benjamin Tan; Andrea Wang-Gillam; Christopher Bognar; Wenhua Chu; Dong Zhou; Robert H Mach; Richard Laforest; Delphine L Chen
Journal:  Radiology       Date:  2016-11-14       Impact factor: 11.105

Review 4.  Trial watch - inhibiting PARP enzymes for anticancer therapy.

Authors:  Antonella Sistigu; Gwenola Manic; Florine Obrist; Ilio Vitale
Journal:  Mol Cell Oncol       Date:  2015-06-10

5.  Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types.

Authors:  Valeria Ossovskaya; Ingrid Chou Koo; Eric P Kaldjian; Christopher Alvares; Barry M Sherman
Journal:  Genes Cancer       Date:  2010-08

Review 6.  Pleiotropic role of PARP1: an overview.

Authors:  Vikas Kumar; Anurag Kumar; Khursheed Ul Islam Mir; Vandana Yadav; Shyam Singh Chauhan
Journal:  3 Biotech       Date:  2021-12-04       Impact factor: 2.406

7.  Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines.

Authors:  T Zaremba; P Ketzer; M Cole; S Coulthard; E R Plummer; N J Curtin
Journal:  Br J Cancer       Date:  2009-06-30       Impact factor: 7.640

8.  Interaction of hepatitis B virus X protein with PARP1 results in inhibition of DNA repair in hepatocellular carcinoma.

Authors:  T-Y Na; N-L Ka; H Rhee; D Kyeong; M-H Kim; J K Seong; Y N Park; M-O Lee
Journal:  Oncogene       Date:  2016-04-04       Impact factor: 9.867

9.  Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.

Authors:  Uffe H Olesen; Jakob G Petersen; Antje Garten; Wieland Kiess; Jun Yoshino; Shin-Ichiro Imai; Mette K Christensen; Peter Fristrup; Annemette V Thougaard; Fredrik Björkling; Peter B Jensen; Søren J Nielsen; Maxwell Sehested
Journal:  BMC Cancer       Date:  2010-12-12       Impact factor: 4.430

10.  Translocation t(11;14) (q13;q32) and genomic imbalances in multi-ethnic multiple myeloma patients: a Malaysian study.

Authors:  Ivyna Bong Pau Ni; Ng Ching Ching; Chang Kian Meng; Zubaidah Zakaria
Journal:  Hematol Rep       Date:  2012-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.